IMV

IMV Earnings Yield

The Earnings Yield of IMV (IMVIF) as of Nov 20, 2026 is -15,863.35 %. In the previous year, Earnings Yield was -15,768.28 % — a change of 0.60% (lower).

Earnings Yield

-15,863.35 %

YoY

0.60%

Last updated:

Earnings Yield of IMV is 2022 -15,863.35 % . Earnings Yield of IMV was 2021 -15,768.28 % . It decreases by 0.60% lower compared to the previous year.

The IMV Earnings Yield history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Earnings Yield
Date
Earnings Yield
Jan 1, 2015
-2,749.28 USD
Jan 1, 2016
-3,896.27 USD
Jan 1, 2017
-5,305.59 USD
Jan 1, 2018
-9,506.73 USD
Jan 1, 2019
-9,108.24 USD
Jan 1, 2020
-11,928.53 USD
Jan 1, 2021
-15,768.28 USD
Jan 1, 2022
-15,863.35 USD
The IMV Earnings Yield history
YEAREarnings YieldYoY
-15,863.35 %+0.60%
-15,768.28 %+32.19%
-11,928.53 %+30.96%
-9,108.24 %-4.19%
-9,506.73 %+79.18%
-5,305.59 %+36.17%
-3,896.27 %+41.72%
-2,749.28 %+0.72%
-2,729.50 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IMV Stock analysis

What does IMV do? IMV, Inc. develops novel cancer immunotherapies and vaccines, focusing on DPX-based cancer vaccines like maveropepimut-S (MVP-S). MVP-S targets survivin, a cancer antigen overexpressed in advanced cancers, and includes an innate immune activator and CD4 T cell helper peptide. It is administered every two months in low doses, driving persistent immune attacks on tumor cells. The company evaluates MVP-S in Phase IIB trials for advanced r/r Diffuse Large B Cell Lymphoma and platinum resistant ovarian cancer. IMV, Inc. generates revenue through clinical development and potential future commercialization of its DPX platform-based therapies. The primary therapeutic candidate, MVP-S, is being tested in Phase IIB trials for specific cancer types, with the company aiming to secure regulatory approvals for these indications. The firm's focus on DPX technology positions it to develop additional cancer vaccines targeting various antigens. The company's target segments include patients with advanced solid or hematological cancers, particularly those with r/r Diffuse Large B Cell Lymphoma and platinum resistant ovarian cancer. These patient groups represent high unmet medical needs, aligning with IMV's focus on developing therapies for difficult-to-treat cancers. IMV's business model relies on advancing clinical trials to demonstrate efficacy and safety, paving the way for potential partnerships or direct sales once approved. IMV is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IMV stock

Earnings Yield of IMV is -15,863.35 % in 2022.

Earnings Yield of IMV changed from -15,768.28 % to -15,863.35 %, representing a 0.60% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Earnings Yield IMV since 2006 – with annual values, charts, and detailed analysis.

Earnings Yield is the inverse of the P/E ratio. It shows the percentage of each dollar invested that was earned by the company. Higher earnings yield indicates better value.

To evaluate Earnings Yield's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Earnings Yield.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Earnings Yield's IMV with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IMV

All Key Metrics — IMV